Sosa-García, 56 patient HCQ ICU study: 11% higher mortality [p=1] https://c19p.org/sosagarcia
copied to clipboard
Experience in the management of severe COVID-19 patients in an intensive care unit
et al., Cir Cir. 2020, 88:5, 569-575, doi:10.24875/CIRU.20000675
Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, p = 1.0.
|
risk of death, 10.5% higher, RR 1.11, p = 1.00, treatment 7 of 38 (18.4%), control 3 of 18 (16.7%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
very late stage, >50% on oxygen/ventilation at baseline, substantial unadjusted confounding by indication likely.
Sosa-García et al., 6/29/2020, retrospective, Mexico, North America, peer-reviewed, baseline oxygen required 100.0%, 6 authors, average treatment delay 9.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.